Biotie Buys Newron In Pain Deal; Price Brings Little Relief
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotie's acquisition of pain-focused Newron for €38 million upfront reflects the trouble Newron was in - and the riskiness of the field.
You may also be interested in...
Germany's Merck Returns Safinamide To Newron, Merger With Biotie Now Under Review
The surprise announcement by Merck Serono to return all rights to safinamide to Italy's Newron has led to Biotie Therapies and Newron reviewing their plans to merge.
Germany's Merck Returns Safinamide To Newron, Merger With Biotie Now Under Review
The surprise announcement by Merck Serono to return all rights to safinamide to Italy's Newron has led to Biotie Therapies and Newron reviewing their plans to merge.
Lundbeck Invests £10M In CNS-Focused Proximagen
Lundbeck's support for Proximagen comes as biotechs struggle for survival in the high-risk CNS space.